# A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis

> **NCT05796245** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 2207 (actual)

## Conditions studied

- Arthritis, Rheumatoid
- Colitis, Ulcerative
- Crohn Disease
- Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05796245
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-01
- **Primary completion:** 2024-03-14
- **Final completion:** 2024-03-14
- **Target enrollment:** 2207 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05796245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05796245, "A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05796245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*